Cardioprotective and Antioxidant Efficiency of Balanites aegyptiaca Extract Against Doxorubicin® Complication

Abstract

Background and Objective: The use of Doxorubicin® (Doxo) in the treatment of different tumours is restricted due to its cardiotoxicity. The objective of this study was to determine the protective effect of Balanites aegyptiaca extract against cardiotoxicity induced by Doxorubicin® in male rats. Materials and Methods: Adult male rats (140-160) were parted into 6 groups (10 animals each) as follows: Group (1) Normal rats the control, group (2) Rats were administered BAE (200 mg kgG1) orally for 4 weeks, group (3) Rats were treated IP with the anticancer drug (Doxorubicin®) at the dose of (0.5 mg kgG1) for 4 weeks, group (4) Administrated orally with BAE in combination with Doxo injection for 4 weeks, group (5) Rats orally with BAE before intoxication with Doxo for 4 weeks and finally group (6) Animals post-administration of BAE for 4 weeks after intoxication with Doxo. After 4 weeks of injections. Results: Revealed that BAE succeeded to decline the Doxorubicin cardiotoxicity, this was evidenced by the significant reduction of serum LDH, CK-MB, total cholesterol, triglycerides, HDL, TNF-α, IL-1β and IL-6 as well as cardiac MDA and nitric oxide levels coupled with marked improvement in serum LDL, PON1 as well as cardiac GSH, SOD and CAT. Moreover, the BAE induced prominent regeneration of the cardiac muscle. Conclusion: Balanites aegyptiaca extract may be a promising cardio-protector against Doxorubicin® toxicity mediated through their antioxidant and radical scavenging activities.